US EditionGroundbreaking HIV prevention shots to begin in Africa
The rollout includes lenacapavir, a twice-yearly injection reducing HIV transmission risk by over 99.9%, aiming to improve adherence and reach UNAIDS targets in high-burden countries.
- A new injectable HIV treatment, Cabotegravir/Rilpivirine , administered every two months, was found to be safe, well tolerated, and preferred by most patients in a study across three African countries.
- The IMPALA study, sponsored by the London School of Hygiene & Tropical Medicine and funded by Janssen Pharmaceutical Companies of Johnson & Johnson, focused on adults whose viral load had remained unsuppressed for two years despite prior antiretroviral therapy .
- The injectable regimen was non-inferior to the standard oral dolutegravir-based therapy among patients who had previously struggled with adherence, offering a promising solution to improve adherence and prevent HIV-related deaths.
68 Articles
68 Articles
Lenacapavir began to be administered on 1 December, which is the first use of this preventive treatment deemed promising in Africa, the continent most affected by the pandemic.
South Africa, Eswatini and Zambia started on Monday to administer the first doses of HIV preventive treatment.
Lenacapavir has been administered since Monday in South Africa, Eswatini and Zambia. It is the first use of this preventive treatment considered promising on the continent, the most affected by the pandemic.
A major HIV campaign is launching in South Africa, Eswatini, and Zambia. The population will be vaccinated with lenacapavir (LEN), a new drug that helps prevent infections. Developed by the pharmaceutical company Gilead Sciences, the drug is administered twice a year. Experts call this a huge step forward compared to PrEP pills, which require one or two daily doses.
South Africa, Eswatini and Zambia must begin on Monday to administer the first doses of HIV preventive treatment, which is the first use of this very promising drug in Africa, the continent most affected by the pandemic. ...
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
